Pringsheim Tamara, Davenport William Jeptha, Marmura Michael J, Schwedt Todd J, Silberstein Stephen
Clinical Neurosciences, University of Calgary Ringgold Standard Institution, Calgary, AB, Canada (T. Pringsheim and W.J. Davenport).
Neurology, Jefferson Headache Center, Philadelphia, PA, USA (M.J. Marmura and S. Silberstein).
Headache. 2016 Jul;56(7):1194-200. doi: 10.1111/head.12870. Epub 2016 Jun 20.
The "Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies" provides levels of evidence for medication efficacy for acute treatment of migraine. The goal of this companion paper is to provide guidance on how to choose between evidence-based treatment options, and, based on the clinical characteristics of the patient and their migraine attacks, to provide guidance on designing an individualized strategy for managing migraine attacks. The acute pharmacological treatments described in the American Headache Society evidence assessment can be divided into those initially taken by the patient during the headache phase of the migraine attack, those taken by the patient later in the attack when initial treatments fail, and those administered intravenously or intramuscularly in urgent care settings. Medications taken initially by patients in the headache phase include nonspecific analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), triptans, and dihydroergotamine (DHE). A stratified approach to treatment is advised, with the choice of medication based on the patient's treatment needs, taking into consideration the attack severity, presence of associated symptoms such as nausea and vomiting, and the degree of migraine-related disability. Individuals with migraine may find reassurance in having a "back-up plan" in the event of an initial acute treatment failure. For those individuals who had a partial response to the initial acute treatment, a second dose might be indicated. When the initial treatment does not provide meaningful and sustained benefits, a treatment from a different medication class is typically chosen. Depending upon the initial treatment used, this might include NSAIDs, triptans, or DHE. Opioids or acetaminophen in combination with codeine or tramadol can be considered as part of the "back-up plan," provided they are used infrequently. When all patient administered treatments have failed and moderate to severe migraine symptoms remain, some individuals seek treatment in urgent care settings. The intravenous administration of antiemetics with or without an intravenous or intramuscular NSAID or DHE, or an intramuscular opioid can be considered. Patients with migraine should be encouraged to treat migraine pain early, and avoid overuse of medications.
《成人偏头痛的急性治疗:美国头痛协会偏头痛药物治疗的证据评估》提供了偏头痛急性治疗药物疗效的证据水平。本配套论文的目的是就如何在循证治疗方案之间进行选择提供指导,并根据患者及其偏头痛发作的临床特征,为设计个体化的偏头痛发作管理策略提供指导。美国头痛协会证据评估中描述的急性药物治疗可分为患者在偏头痛发作的头痛期最初服用的药物、在发作后期初始治疗失败时服用的药物,以及在紧急护理环境中静脉注射或肌肉注射的药物。患者在头痛期最初服用的药物包括非特异性镇痛药,如对乙酰氨基酚和非甾体抗炎药(NSAIDs)、曲坦类药物和双氢麦角胺(DHE)。建议采用分层治疗方法,根据患者的治疗需求选择药物,同时考虑发作的严重程度、恶心和呕吐等伴随症状的存在以及偏头痛相关残疾的程度。偏头痛患者在初始急性治疗失败时若有“备用方案”可能会感到安心。对于那些对初始急性治疗有部分反应的个体,可能需要服用第二剂。当初始治疗未提供有意义且持续的益处时,通常会选择不同药物类别的治疗方法。根据所使用的初始治疗方法,这可能包括NSAIDs、曲坦类药物或DHE。阿片类药物或对乙酰氨基酚与可待因或曲马多的组合可作为“备用方案”的一部分,但前提是不经常使用。当所有患者自行给药的治疗均失败且中度至重度偏头痛症状仍然存在时,一些个体寻求在紧急护理环境中接受治疗。可考虑静脉注射止吐药,可联合或不联合静脉注射或肌肉注射的NSAIDs或DHE,或肌肉注射阿片类药物。应鼓励偏头痛患者尽早治疗偏头痛疼痛,并避免过度使用药物。